U.K. biotechnology company Microscience reported positive results from clinical trials in the United States of its oral typhoid vaccine for travelers. According to the company, the tests involving 60 volunteers indicated that a single dose of the vaccine provided the same level of immune protection as existing commercial typhoid vaccines. The new vaccine uses genetically altered live typhoid bacteria that cannot cause disease but which prime the immune system to resist infection.